Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 1
2005 1
2006 5
2007 4
2008 7
2009 6
2010 13
2011 19
2012 16
2013 18
2014 28
2015 30
2016 29
2017 40
2018 44
2019 44
2020 43
2021 56
2022 56
2023 76
2024 80
2025 90
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

646 results

Results by year

Filters applied: . Clear all
Page 1
A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma.
Huang KB, Gui CP, Xu YZ, Li XS, Zhao HW, Cao JZ, Chen YH, Pan YH, Liao B, Cao Y, Zhang XK, Han H, Zhou FJ, Liu RY, Chen WF, Jiang ZY, Feng ZH, Jiang FN, Yu YF, Xiong SW, Han GP, Tang Q, Ouyang K, Qu GM, Wu JT, Cao M, Dong BJ, Huang YR, Zhang J, Li CX, Li PX, Chen W, Zhong WD, Guo JP, Liu ZP, Hsieh JT, Xie D, Cai MY, Xue W, Wei JH, Luo JH. Huang KB, et al. Nat Commun. 2024 Jul 23;15(1):6215. doi: 10.1038/s41467-024-50369-y. Nat Commun. 2024. PMID: 39043664 Free PMC article.
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Deng J, Paulus A, Fang DD, Manna A, Wang G, Wang H, Zhu S, Chen J, Min P, Yin Y, Dutta N, Halder N, Ciccio G, Copland JA, Miller J, Han B, Bai L, Liu L, Wang M, McEachern D, Przybranowski S, Yang CY, Stuckey JA, Wu D, Li C, Ryan J, Letai A, Ailawadhi S, Yang D, Wang S, Chanan-Khan A, Zhai Y. Deng J, et al. Among authors: li c. Clin Cancer Res. 2022 Dec 15;28(24):5455-5468. doi: 10.1158/1078-0432.CCR-21-4037. Clin Cancer Res. 2022. PMID: 36048524
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.
Chen SY, Xu PP, Feng R, Cui GH, Wang L, Cheng S, Mu RJ, Zhang HL, Wei XL, Song YP, Ding KY, Dong LH, Zhu ZM, Yang SM, Wang X, Liu TB, Hu JD, Zheng XY, Bai O, Xu JY, Huang L, Sang W, Shi KQ, Zhou F, Li F, Liang AB, Zhou H, Hao SG, Huang HH, Xu B, Qian WB, Li CX, Li ZM, Wu CY, Wang XB, Shi WY, Wang SY, Tian YY, Zhang X, Zhou KS, Cui LJ, Liu H, Tan H, Leng Q, Zhao DL, Niu T, Zhao WL. Chen SY, et al. Cancer Commun (Lond). 2025 Aug;45(8):919-935. doi: 10.1002/cac2.70033. Epub 2025 May 8. Cancer Commun (Lond). 2025. PMID: 40344323 Free PMC article.
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.
Gui CP, Chen YH, Zhao HW, Cao JZ, Liu TJ, Xiong SW, Yu YF, Liao B, Cao Y, Li JY, Huang KB, Han H, Zhang ZL, Chen WF, Jiang ZY, Gao Y, Han GP, Tang Q, Ouyang K, Qu GM, Wu JT, Guo JP, Li CX, Li PX, Liu ZP, Hsieh JT, Cai MY, Li XS, Wei JH, Luo JH. Gui CP, et al. Lancet Digit Health. 2023 Aug;5(8):e515-e524. doi: 10.1016/S2589-7500(23)00095-X. Epub 2023 Jun 29. Lancet Digit Health. 2023. PMID: 37393162 Free article.
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, Yang X, Yang C, Xue S, Qiu H, Miao M, Chen S, Jin Z, Fu C, Li C, Sun A, Han Y, Wang Y, Yu L, Wu D, Cui Q, Tang X. Liu S, et al. Among authors: li c. Blood Cancer J. 2023 Apr 24;13(1):60. doi: 10.1038/s41408-023-00819-5. Blood Cancer J. 2023. PMID: 37095120 Free PMC article.
646 results